Sterile Water for Injection, USP (SWFI) contains water that has been purified by reverse osmosis and deionized by the use of advanced technologies so that it meets or exceeds the United States Pharmacopeia (USP) standards for sterility, physical qualities, and purity. SWFI has an ionic content of < 10 mg/L (TDS). It is commonly used in clinical applications where water is used as a vehicle or diluent for other medications.
Sterile Water for Injection (SWFI) is sterile water that has been made free of harmful microorganisms so it can be used as an injection. SWFI is used in both hospitals and doctors’ offices to give injections to patients or to prepare and clean an area before giving an injection. Sterile Water for Injection is sterile, non-pyrogenic water for injection, USP. The pH range is 3.5–7.0 and the osmolality range is 50–300 mOsm/kg (calc).
Sterile products are most frequently solution or suspensions, but may even be solid pellets for tissue implementation. The manufacturing of parenterals has become a highly specialized area in pharmaceutical processing.
Sterile facilities for all pharmaceutical product specially to parentral preparation, is a must important back bone of sterile formulation andor pharmaceutical dosage form. There is most important to sterile of the areas where the formulation process proceed from initial to final stage. The sterile injectable products are very critical and sensitive products as they are administered directly into blood circulation.
Sterile Water for Injection is indicated for use only as a solvent or diluents vehicle for parenterally administered drugs or solutions and as a source of water for parenteral fluid replenishment after suitable additives are introduced to avoid tonicity of the blood. In some cases, it may be used as a lavage or rinsing agent, but isotonic solutions suitable to the area of exposure are preferred if available. When administered intravenously as a vehicle for drugs, Sterile Water for Injection provides a source of water for parenteral fluid replenishment after proper osmolarity has been achieved.
India's biotechnology industry comprising biopharmaceuticals, bio-services, bio-agriculture, bio-industry, and bioinformatics is expected grow at an average growth rate of around 30 per cent a y-o-y to reach US$ 100 billion by 2025.
The increase of lifestyle diseases in India such as diabetes and heart disease has heightened the demand for medicines. There is a large pool of scientific and research expertise in India, and an enormous population with high incidences of cancer and chronic disease. The shorter recruitment time-frames and lower costs make India an ideal setting for drug development and clinical trials.
Indian pharmaceutical sector is expected to grow to US$ 100 billion, while medical device market is expected to grow US$ 25 billion by 2025. Pharmaceuticals export from India stood at US$ 20.70 billion in FY20. Pharmaceutical export include bulk drugs, intermediates, drug formulations, biologicals, Ayush and herbal products and surgical.
Key Players
· Albert David Ltd.
· Amanta Healthcare Ltd.
· Chandra Bhagat Pharma Ltd.
· Denis Chem Lab Ltd.
· Health Biotech Ltd.
· Ivy Health & Life Sciences Pvt. Ltd.
